Bacterial infections caused by gram-positive strains remain one of the major causes
of admission to intensive care units. Pathogens such as Staphylococcus aureus, Enterococci, and Streptococcus pneumonia have had significant roles in increasing the mortality and morbidity of diseases
ranging from minor skin infections to bacteremia, endocarditis, necrotizing pneumonia,
and toxic shock syndrome (TSS).
1
,2
Along with the development of antibiotics, drug resistance by the next generations
of bacteria has created new challenges. Therefore, prescribing the appropriate antibacterial
regimen is crucial, as the use of each antibiotic affects the bacterial ecology and
the corresponding resistance to it. The emergence of multi-drug-resistant germs threatens
practitioners’ ability to treat health problems and increases the cost of health care.
1
,3
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of the Medical SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Infections caused by Gram-positive bacteria: a review of the global challenge.J Infect. 2009; 59: S4-S16
- Epidemiology and microbiology of gram-positive bloodstream infections in a tertiary-care hospital in Beijing, China: a 6-year retrospective study.Antimicrob Resist Infect Control. 2018; 7: 107
- The bacterial challenge: time to react.Eur Cent Dis Prev Control. 2009;
- Mayo Clinic Proceedings.Elsevier, 2011
- The empirical combination of vancomycin and a β-lactam for staphylococcal bacteremia.Clin Infect Dis. 2013; 57: 1760-1765
- Methicillin-resistant S. aureus infections among patients in the emergency department.New Engl J Med. 2006; 355: 666-674
- Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992–2003.Clin Infect Dis. 2006; 42: 389-391
- The 10×’20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.Clin Infect Dis. 2010; 50: 1081-1083
- A 55-year-old man with fever, renal failure, and hip pain.Chest. 2001; 119: 281-284
- The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis.J Infect Dis. 1988; 158: 23-28
- Antimicrobial combinations.Antibiot Lab Med. 1991; : 432-492
- In vitro antagonism with the combination of vancomycin and clindamycin against Staphylococcus aureus.J Appl Res Clin Exp Therap. 2004; 4: 385-395
- Clindamycin suppresses virulence expression in inducible clindamycin-resistant Staphylococcus aureus strains.Ann Clin Microbiol Antimicrob. 2018; 17: 1-6
- Potential of clindamycin in addition to vancomycin for the treatment of oxacillin-resistant Staphylococcus aureus septicemia persisting under vancomycin therapy.Int J Antimicrob Agents. 1995; 5: 123-128
- Vancomycin combined with clindamycin for the treatment of acute bacterial skin and skin-structure infections.Clin Infect Dis. 2015; 61: 1148-1154
- In vitro evaluation of clindamycin in combination with oxacillin, rifampin, or vancomycin againstStaphylococcus aureus.Diagn Microbiol Infect Dis. 1986; 4: 133-138
- What in vitro models of infection can and cannot do.Pharmacotherapy. 2001; 21: 292S-301S
Article info
Publication history
Published online: June 12, 2022
Accepted:
June 9,
2022
Received:
September 9,
2020
Identification
Copyright
© 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.
